Eli Lilly and Company (BVMF:LILY34)

Market Cap	4.91T
Revenue (ttm)	316.67B
Net Income (ttm)	98.13B
Shares Out	n/a
EPS (ttm)	108.94
PE Ratio	50.02
Forward PE	32.73
Dividend	0.75 (0.41%)
Ex-Dividend Date	Nov 13, 2025

Volume	12,155
Average Volume	20,709
Open	183.44
Previous Close	183.47
Day's Range	178.06 - 183.44
52-Week Range	113.00 - 208.36
Beta	0.39
RSI	53.37
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD